Shanghai Yizhong Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 688091.SS

Shanghai Yizhong Pharmaceutical Co., Ltd. Free Cash Flow Yield on January 14, 2025: 1.10%

Shanghai Yizhong Pharmaceutical Co., Ltd. Free Cash Flow Yield is 1.10% on January 14, 2025, a 34.27% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Shanghai Yizhong Pharmaceutical Co., Ltd. 52-week high Free Cash Flow Yield is 2.45% on July 24, 2024, which is 123.52% above the current Free Cash Flow Yield.
Shanghai Yizhong Pharmaceutical Co., Ltd. 52-week low Free Cash Flow Yield is 0.74% on November 13, 2024, which is -32.54% below the current Free Cash Flow Yield.
Shanghai Yizhong Pharmaceutical Co., Ltd. average Free Cash Flow Yield for the last 52 weeks is 1.35%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Shanghai Stock Exchange: 688091.SS

Shanghai Yizhong Pharmaceutical Co., Ltd.

CEO	Mr. Jingsong Zhou
IPO Date	Sept. 9, 2021
Location	China
Headquarters	No.79 Renqi Road
Employees	304
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It develops a dosage form of paclitaxel, an anti-tumor chemotherapeutic. The company was founded in 2009 and is based in Shanghai, China.

Key trends

Past 5 years